Who are sirolimus versus mycophenolate mofetil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sirolimus (drug), mmf (drug), AZATHIOPRINE or METHOTREXATE, Infliximab and immunosuppressives, Cyclophosphamide and azathioprine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sirolimus-versus-mycophenolate-mofetil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

sirolimus versus mycophenolate mofetil — Competitive Intelligence Brief

sirolimus versus mycophenolate mofetil (sirolimus versus mycophenolate mofetil) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive agents. Area: Immunology / Transplantation.

phase 3 Immunosuppressive agents mTOR (sirolimus); IMPDH (mycophenolate mofetil) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

sirolimus versus mycophenolate mofetil (sirolimus versus mycophenolate mofetil) — EUROSPK Study Group. This is a comparative study of two immunosuppressive agents: sirolimus (mTOR inhibitor) and mycophenolate mofetil (IMPDH inhibitor), used to prevent organ rejection.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
sirolimus versus mycophenolate mofetil TARGET	sirolimus versus mycophenolate mofetil	EUROSPK Study Group	phase 3	Immunosuppressive agents	mTOR (sirolimus); IMPDH (mycophenolate mofetil)
sirolimus (drug), mmf (drug)	sirolimus (drug), mmf (drug)	University Hospital Muenster	marketed	Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination)	mTOR (sirolimus); IMPDH type II (MMF)
AZATHIOPRINE or METHOTREXATE	AZATHIOPRINE or METHOTREXATE	Prof. Arie Levine	marketed	Immunosuppressive agents / Antimetabolites	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) for azathioprine; Dihydrofolate reductase (DHFR) for methotrexate
Infliximab and immunosuppressives	Infliximab and immunosuppressives	Children's Hospital of Fudan University	marketed	TNF-α inhibitor (monoclonal antibody) + immunosuppressive agents	TNF-α receptor (via infliximab); multiple targets depending on co-administered immunosuppressive
Cyclophosphamide and azathioprine	Cyclophosphamide and azathioprine	Assistance Publique - Hôpitaux de Paris	phase 3	Immunosuppressive agents / Cytotoxic agents

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive agents class)

EUROSPK Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sirolimus versus mycophenolate mofetil — Competitive Intelligence Brief. https://druglandscape.com/ci/sirolimus-versus-mycophenolate-mofetil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab